Department of Paediatrics, Turku University Hospital, Finland.
Lancet Infect Dis. 2011 Jan;11(1):23-9. doi: 10.1016/S1473-3099(10)70255-3. Epub 2010 Nov 22.
Few prospectively collected data are available to support the effectiveness of inactivated influenza vaccines in children younger than 2 years. We aimed to establish the effectiveness of trivalent inactivated influenza vaccine against laboratory-confirmed influenza A and B infections in a cohort of children younger than 3 years.
In a prospective cohort study during the influenza season of 2007-08 in Turku, Finland, between Jan 14 and April 9, 2008, we assessed the effectiveness of trivalent inactivated influenza vaccine against laboratory-confirmed influenza A and B infections in children aged 9 months to 3 years. Our study was part of a clinical trial on antiviral treatment of influenza in children (ClinicalTrials.gov, number NCT00593502). The vaccine was given as part of the Finnish vaccination programme as a 0·5 mL injection. Children enrolled into our study through mailed announcements and local advertisements were examined every time they had fever or signs of respiratory infection. No exclusion criteria were used for enrolment. Influenza was diagnosed with viral culture, antigen detection, and RT-PCR assays of nasal swab specimens. Vaccination status of children was determined by parental report. We calculated the primary effectiveness of influenza vaccination by comparing the proportions of infections in fully vaccinated and unvaccinated children in the follow-up cohort.
We enrolled 631 children into our study with a mean age of 2·13 years (range 9-40 months). Seven (5%) of 154 fully vaccinated children and 61 (13%) of 456 unvaccinated children contracted influenza during the study (effectiveness 66%, 95% CI 29-84; p=0·003). In the subgroup of children younger than 2 years, four (4%) of 96 fully vaccinated children and 21 (12%) of 172 unvaccinated children contracted influenza (66%, 9-88, p=0·03). We were unable to record any adverse events associated with the vaccination of the children in our study.
Trivalent inactivated influenza vaccine was effective in preventing influenza in young children, including those younger than 2 years. Our findings suggest that influenza vaccine recommendations should be reassessed in most countries.
F Hoffmann-La Roche Ltd.
目前仅有少量前瞻性收集的数据支持在 2 岁以下儿童中使用流感灭活疫苗的有效性。本研究旨在确定三价流感灭活疫苗在 3 岁以下儿童队列中预防实验室确诊的甲型和乙型流感感染的有效性。
在 2007-08 年流感季节期间,于 2008 年 1 月 14 日至 4 月 9 日在芬兰图尔库进行了一项前瞻性队列研究,评估了三价流感灭活疫苗在 9 个月至 3 岁儿童中预防实验室确诊的甲型和乙型流感感染的有效性。本研究是儿童抗流感病毒治疗的临床试验的一部分(ClinicalTrials.gov,编号 NCT00593502)。疫苗作为芬兰免疫接种计划的一部分,通过 0.5ml 注射给予。通过邮寄通告和当地广告招募参加我们研究的儿童每次发热或出现呼吸道感染症状时都接受检查。入组没有排除标准。通过病毒培养、抗原检测和鼻拭子 RT-PCR 检测来诊断流感。儿童的疫苗接种情况通过父母报告确定。我们通过比较随访队列中完全接种疫苗和未接种疫苗儿童的感染比例来计算流感疫苗的初级有效性。
我们共纳入了 631 名平均年龄为 2.13 岁(9-40 个月)的儿童进行研究。在研究期间,154 名完全接种疫苗的儿童中有 7 名(5%)和 456 名未接种疫苗的儿童中有 61 名(13%)感染了流感(有效性 66%,95%CI 29-84;p=0.003)。在 2 岁以下儿童亚组中,96 名完全接种疫苗的儿童中有 4 名(4%)和 172 名未接种疫苗的儿童中有 21 名(12%)感染了流感(66%,9-88,p=0.03)。我们无法记录与儿童接种疫苗相关的任何不良事件。
三价流感灭活疫苗在预防幼儿,包括 2 岁以下儿童的流感方面有效。我们的研究结果表明,应重新评估大多数国家的流感疫苗推荐意见。
罗氏公司。